BSE Live
Mar 11, 16:01Prev. Close
1490.30
Open Price
1490.40
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Mar 11, 15:56Prev. Close
1491.20
Open Price
1491.50
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1533.90 (111)
| Balance Sheet of Ipca Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||||
| SHAREHOLDER'S FUNDS | ||||||
| Equity Share Capital | 25.37 | 25.37 | 25.37 | 25.37 | 25.37 | |
| Total Share Capital | 25.37 | 25.37 | 25.37 | 25.37 | 25.37 | |
| Reserves and Surplus | 6,866.25 | 6,323.34 | 5,851.93 | 5,497.97 | 4,727.35 | |
| Total Reserves and Surplus | 6,866.25 | 6,323.34 | 5,851.93 | 5,497.97 | 4,727.35 | |
| Total Shareholders Funds | 6,891.62 | 6,348.71 | 5,877.30 | 5,523.34 | 4,752.72 | |
| NON-CURRENT LIABILITIES | ||||||
| Long Term Borrowings | 482.43 | 542.19 | 651.78 | 395.18 | 9.13 | |
| Deferred Tax Liabilities [Net] | 191.20 | 183.09 | 179.45 | 155.14 | 135.00 | |
| Other Long Term Liabilities | 28.38 | 14.62 | 14.09 | 12.92 | 10.40 | |
| Long Term Provisions | 57.76 | 50.49 | 46.57 | 40.98 | 37.29 | |
| Total Non-Current Liabilities | 759.77 | 790.39 | 891.89 | 604.22 | 191.82 | |
| CURRENT LIABILITIES | ||||||
| Short Term Borrowings | 389.30 | 590.72 | 770.83 | 365.83 | 214.07 | |
| Trade Payables | 481.53 | 422.74 | 450.84 | 480.41 | 526.46 | |
| Other Current Liabilities | 417.60 | 397.63 | 348.24 | 392.44 | 222.78 | |
| Short Term Provisions | 131.10 | 109.08 | 107.87 | 100.62 | 102.28 | |
| Total Current Liabilities | 1,419.53 | 1,520.17 | 1,677.78 | 1,339.30 | 1,065.59 | |
| Total Capital And Liabilities | 9,070.92 | 8,659.27 | 8,446.97 | 7,466.86 | 6,010.13 | |
| ASSETS | ||||||
| NON-CURRENT ASSETS | ||||||
| Tangible Assets | 2,502.78 | 2,502.09 | 2,454.58 | 2,057.31 | 1,839.75 | |
| Intangible Assets | 33.93 | 21.47 | 24.08 | 27.47 | 28.85 | |
| Capital Work-In-Progress | 484.05 | 165.59 | 114.31 | 285.29 | 180.85 | |
| Other Assets | 0.26 | 0.14 | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 3,026.62 | 2,698.90 | 2,601.68 | 2,373.82 | 2,050.60 | |
| Non-Current Investments | 2,041.32 | 2,243.56 | 733.41 | 728.21 | 474.01 | |
| Deferred Tax Assets [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Long Term Loans And Advances | 31.96 | 88.20 | 115.86 | 63.88 | 138.95 | |
| Other Non-Current Assets | 152.97 | 118.72 | 120.87 | 110.03 | 68.78 | |
| Total Non-Current Assets | 5,252.87 | 5,149.38 | 3,571.82 | 3,275.94 | 2,732.34 | |
| CURRENT ASSETS | ||||||
| Current Investments | 651.94 | 410.60 | 323.32 | 719.31 | 393.83 | |
| Inventories | 1,542.39 | 1,677.09 | 1,660.13 | 1,750.15 | 1,517.09 | |
| Trade Receivables | 1,154.61 | 1,027.40 | 925.90 | 815.94 | 774.46 | |
| Cash And Cash Equivalents | 164.53 | 112.92 | 1,706.06 | 592.97 | 306.92 | |
| Short Term Loans And Advances | 40.37 | 5.43 | 1.03 | 7.46 | 19.96 | |
| OtherCurrentAssets | 264.21 | 276.45 | 258.71 | 305.09 | 265.53 | |
| Total Current Assets | 3,818.05 | 3,509.89 | 4,875.15 | 4,190.92 | 3,277.79 | |
| Total Assets | 9,070.92 | 8,659.27 | 8,446.97 | 7,466.86 | 6,010.13 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||||
| Contingent Liabilities | 490.63 | 308.45 | 2,161.85 | 287.71 | 382.20 | |
| CIF VALUE OF IMPORTS | ||||||
| Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||||
| Expenditure In Foreign Currency | 717.42 | 727.91 | 817.75 | 893.54 | 794.87 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | ||||||
| FOB Value Of Goods | 2,808.96 | 2,707.70 | 2,643.42 | 2,502.69 | 2,717.19 | |
| Other Earnings | -- | -- | -- | -- | -- | |
| BONUS DETAILS | ||||||
| Bonus Equity Share Capital | 10.45 | 10.45 | 10.45 | 10.45 | 20.90 | |
| NON-CURRENT INVESTMENTS | ||||||
| Non-Current Investments Quoted Market Value | 2,788.11 | -- | -- | -- | -- | |
| Non-Current Investments Unquoted Book Value | 629.00 | 18.60 | 25.41 | 25.19 | -- | |
| CURRENT INVESTMENTS | ||||||
| Current Investments Quoted Market Value | 651.94 | 410.60 | 323.32 | 719.31 | 393.83 | |
| Current Investments Unquoted Book Value | -- | -- | -- | -- | -- |
10.03.2026
Astal Lab Standalone December 2025 Net Sales at Rs 52.24 crore, up 261.27% Y-o-Y
09.03.2026
06.03.2026
Buy Ipca Laboratories; target of Rs 1800: Prabhudas Lilladher
06.03.2026
26.11.2025
Ipca Labs Consolidated September 2025 Net Sales at Rs 2,556.50 crore, up 8.56% Y-o-Y
24.11.2025
Ipca Labs Standalone September 2025 Net Sales at Rs 1,930.32 crore, up 6.59% Y-o-Y
05.09.2025
Ipca Labs Standalone June 2025 Net Sales at Rs 1,746.90 crore, up 11.56% Y-o-Y
10.06.2025
Ipca Labs Standalone March 2025 Net Sales at Rs 1,638.44 crore, up 8.46% Y-o-Y
26.11.2025
Ipca Labs Consolidated September 2025 Net Sales at Rs 2,556.50 crore, up 8.56% Y-o-Y
24.11.2025
Ipca Labs Standalone September 2025 Net Sales at Rs 1,930.32 crore, up 6.59% Y-o-Y
05.09.2025
Ipca Labs Standalone June 2025 Net Sales at Rs 1,746.90 crore, up 11.56% Y-o-Y
10.06.2025
Ipca Labs Standalone March 2025 Net Sales at Rs 1,638.44 crore, up 8.46% Y-o-Y
11.03.2026
Granules India looks for M&A as it expands beyond the US, deepens focus on complex generics
11.03.2026
10.03.2026
Beyond the price war, Indian drug companies gearing up to win the GLP-1 retention game
10.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
22.01.2026
Dr Reddy’s stock jumps over 4% today as brokerages turn bullish after Q3 results beat estimates
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
22.01.2026
Dr Reddy’s stock jumps over 4% today as brokerages turn bullish after Q3 results beat estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities